Early versus delayed, provisional eptifibatideinacutecoronarysyndromes.NEnglJMed.2009;360:2176 90. 296. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopi- dogrel and aspirin followed by long-term therapy in patients undergo- ing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527 33. 297. Ottervanger JP, Armstrong P, Barnathan ES, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV Acute Coronary Syndrome) Trial. Circulation. 2003;107:437 42. 298. Berger JS, Sallum RH, Katona B, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J. 2012;164:153 62. 299. Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresis- tance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127:377 85. 300. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percu- taneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923 32. 301. Plaivx. Bristol-Myers Squibb: New York, NY. 2013. 302. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopi- dogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001 15. 303. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297 309. 304. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasu- grel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999 1010. 305. Becker RC, Bassand JP, Budaj A, et al. 